NT-proBNP: Why the Go-To Heart Failure Blood Test Works Better for Some Types Than Others
NT-proBNP is the gold standard blood test for heart failure, but it's much less reliable for diagnosing the preserved-ejection-fraction subtype, where age, kidney function, and obesity muddy the results.
Quick Facts
What This Study Found
NT-proBNP remains the gold standard biomarker for diagnosing and assessing prognosis in heart failure, but its performance differs significantly between heart failure subtypes. In HFrEF (reduced ejection fraction), elevated NT-proBNP levels strongly correlate with the severity of ventricular dysfunction and reliably guide treatment decisions. However, in HFpEF (preserved ejection fraction), NT-proBNP's diagnostic specificity is reduced because levels are confounded by age, kidney function, and obesity — meaning doctors often need additional imaging or biomarkers to confirm the diagnosis.
The review highlights emerging proteomic biomarkers like soluble ST2 and GDF-15 that complement NT-proBNP by reflecting different molecular pathways of heart remodeling and inflammation. The authors argue that multimarker strategies combining NT-proBNP with these newer biomarkers will be necessary for precision-based heart failure management.
Key Numbers
37+ million people affected by HF worldwide · NT-proBNP = gold standard biomarker · Diagnostic specificity reduced in HFpEF · Novel markers: soluble ST2, GDF-15
How They Did This
Narrative review integrating current evidence on NT-proBNP's pathophysiology, clinical thresholds, predictive capacity across heart failure phenotypes, and emerging proteomic biomarkers. Published in Cureus.
Why This Research Matters
Heart failure affects over 37 million people worldwide, and correctly distinguishing between HFpEF and HFrEF is critical because the treatments differ. NT-proBNP is the most widely used peptide biomarker in cardiology, but its limitations in HFpEF leave a diagnostic gap. Understanding where this peptide biomarker works well and where it falls short is essential for improving heart failure care.
The Bigger Picture
NT-proBNP is one of the most important peptide biomarkers in all of medicine, used millions of times each year to diagnose and monitor heart failure. This review sits at the intersection of peptide biology and precision medicine, showing how a single peptide measurement is both indispensable and insufficient — and why the future lies in multimarker panels that combine peptide biomarkers with proteomic discoveries.
What This Study Doesn't Tell Us
As a narrative review, it synthesizes existing evidence rather than presenting new data. Published in Cureus, which has a less rigorous peer review process than top-tier cardiology journals. Does not provide specific quantitative thresholds or meta-analytic data comparing biomarker performance.
Questions This Raises
- ?Can a multimarker panel including NT-proBNP, soluble ST2, and GDF-15 reliably distinguish HFpEF from HFrEF in a prospective clinical trial?
- ?How should NT-proBNP thresholds be adjusted for obese patients to improve HFpEF diagnosis?
- ?Will proteomic approaches identify entirely new peptide biomarkers that outperform NT-proBNP for specific heart failure subtypes?
Trust & Context
- Key Stat:
- 37 million+ People worldwide affected by heart failure, the condition NT-proBNP is used to diagnose and monitor
- Evidence Grade:
- This is a narrative review published in Cureus, which provides a useful synthesis but lacks the systematic methodology and impact factor of reviews in top cardiology journals. The underlying evidence on NT-proBNP is well-established from decades of research.
- Study Age:
- Published in 2025. Reflects the current state of knowledge on NT-proBNP and emerging proteomic biomarkers in heart failure.
- Original Title:
- N‑Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) as a Biomarker in Heart Failure With Preserved Ejection Fraction (HFpEF) Versus Heart Failure With Reduced Ejection Fraction (HFrEF): The Way Forward in the Age of Proteomics.
- Published In:
- Cureus, 17(10), e94162 (2025)
- Authors:
- Kanyal, Shweta, Das, Abhirami(2), Bashir, Anas M Din, Syed, Ahmed H, Aujla, Savvy, Chaudhary, Jainam, Patel, Dharmik, Goel, Ashish
- Database ID:
- RPEP-11715
Evidence Hierarchy
Frequently Asked Questions
What is NT-proBNP and why do doctors test for it?
NT-proBNP is a peptide fragment released by the heart when it's under stress or strain. Doctors use a simple blood test to measure it — high levels suggest heart failure. It's the most widely used biomarker for diagnosing heart failure and tracking how well treatment is working.
Why doesn't NT-proBNP work as well for all types of heart failure?
In heart failure with preserved ejection fraction (HFpEF), the heart still pumps normally but is stiff and doesn't fill well. NT-proBNP levels in these patients are often lower and can be skewed by age, obesity, and kidney function, making the test less specific. Doctors frequently need echocardiography or additional biomarkers to confirm the diagnosis.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11715APA
Kanyal, Shweta; Das, Abhirami; Bashir, Anas M Din; Syed, Ahmed H; Aujla, Savvy; Chaudhary, Jainam; Patel, Dharmik; Goel, Ashish. (2025). N‑Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) as a Biomarker in Heart Failure With Preserved Ejection Fraction (HFpEF) Versus Heart Failure With Reduced Ejection Fraction (HFrEF): The Way Forward in the Age of Proteomics.. Cureus, 17(10), e94162. https://doi.org/10.7759/cureus.94162
MLA
Kanyal, Shweta, et al. "N‑Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) as a Biomarker in Heart Failure With Preserved Ejection Fraction (HFpEF) Versus Heart Failure With Reduced Ejection Fraction (HFrEF): The Way Forward in the Age of Proteomics.." Cureus, 2025. https://doi.org/10.7759/cureus.94162
RethinkPeptides
RethinkPeptides Research Database. "N‑Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) as a B..." RPEP-11715. Retrieved from https://rethinkpeptides.com/research/kanyal-2025-nterminal-probtype-natriuretic-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.